Hong Kong-based Insilico, which uses machine learning to identify potential drug targets, raised $35M from Prosperity7, bringing its total Series D to $95M (Rita Liao/TechCrunch)

Hong Kong-based Insilico, which uses machine learning to identify potential drug targets, raised $35M from Prosperity7, bringing its total Series D to $95M (Rita Liao/TechCrunch)

Rita Liao / TechCrunch:
Hong Kong-based Insilico, which uses machine learning to identify potential drug targets, raised $35M from Prosperity7, bringing its total Series D to $95M  —  Hong Kong-based drug discovery and development company Insilico has secured fresh capital at a time that its CEO described as a “biotech winter.”